Suzhou Abogen Biosciences, a Chinese vaccine developer targeting COVID-19, raised a USD700m Series C from Temasek, Loyal Valley Capital, Lilly Asia Ventures, Invesco Developing Markets Fund, GL Ventures, Yunfeng Capital and Boyu Capital. Youshan Capital, Gaorong Capital, Firstred Capital, Octagon Capital, Kaiser, 5Y Capital, MSA Capital, Alwin Capital, Yingke PE, Tiger Jade Capital, AIHC Capital, Richfields Capital, Oriental Spring and Legend Capital also participated in the round. Existing investors including Qiming Venture Partners, Highlight Capital, PICC Capital, BioTrack Capital, CTS Capital reupped. Read more